CLINICAL QUESTION: How effective are tocolytics for the treatment of preterm labor?
BACKGROUND: Tocolytic drugs have not been shown to reduce the number of preterm deliveries but may prolong pregnancy for up to 48 hours. Postponing delivery may allow the administration of corticosteroid drugs to enhance pulmonary maturity and reduce the severity of respiratory distress syndrome.1
POPULATION STUDIED: The patients included were women in a referred care setting presenting with preterm labor. Seventeen studies published from 1966 to 1997 involving 2785 patients met the final criteria. Five studies used ritodrine as the tocolytic; 4 used magnesium sulfate; 3 used indomethacin; 2 used terbutaline; 2 used atosiban; 1 used isoxsuprine; and 1 used ethanol.
STUDY DESIGN AND VALIDITY: The authors conducted a comprehensive search of MEDLINE and the Cochrane Controlled Trials Register to identify articles for this review. A study was included if it was a placebo-controlled randomized trial evaluating the effect of a tocolytic on women in preterm labor and reported perinatal, neonatal, or maternal outcomes.
OUTCOMES MEASURED: The primary outcomes measured were duration of prolonged pregnancy, perinatal/neonatal outcomes, and maternal adverse effects. Meta-analyses were done for each outcome for all trials and for specific types of tocolytic therapy when possible.
RESULTS: Tocolytics decreased the likelihood of delivery within 24 hours (odds ratio [OR] = 0.47; 95% confidence interval [CI], 0.29 - 0.77), 48 hours (OR = 0.57; 95% CI, 0.38 - 0.83), and 7 days (OR = 0.60; 95% CI, 0.38 - 0.95). Specifically, betamimetics, indomethacin, atosiban, and ethanol (but not magnesium sulfate) were associated with significant prolongation of pregnancy. Tocolytics were not associated with significant reduction in births before 30, 32, or 37 weeks’ gestation. Tocolytics were not associated with significantly reduced rates of perinatal death, respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, patent ductus arteriosus, neonatal sepsis, seizures, hypoglycemia, or birth weight of >2500 grams. Maternal adverse effects significantly associated with tocolytic use were palpitations, nausea, tremor, chorioamnionitis, hyperglycemia, hypo- kalemia, and the need to discontinue treatment. Specifically, betamimetics were associated with increases in most maternal side effects.
Tocolytic drugs can prolong pregnancy for at least 48 hours and possibly up to 7 days, but there is no convincing evidence of reduction in preterm delivery or perinatal morbidity or mortality. The delay in delivery afforded by a tocolytic agent, however, allows time for the administration of corticosteroids, which is associated with a significant reduction in neonatal morbidity and mortality.1,2 The neonatal benefits of tocolysis combined with steroid administration may outweigh the maternal risks, particularly in the setting of extreme prematurity.